SPRO

Spero Therapeutics Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↓ 0/10
  • Value↓ 4/10
Spero Therapeutics sales and earnings growth
SPRO Growth
Low
  • Revenue Y/Y↑ 39.24%
  • EPS Y/Y↑ 111.81%
  • FCF Y/Y↑ 46.15%
Spero Therapeutics gross and profit margin trends
SPRO Profitability
Good
  • Gross margin ↑ 100.00%
  • EPS margin↑ 12.80%
  • ROIC 5Y↑ -173.92%
Spero Therapeutics net debt vs free cash flow
SPRO Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Spero Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks